



STIC Search Report

EIC 1700

STIC Database Tracking Number: 161807

**TO: Ben Sackey
Location: Rem 5B31
Art Unit : 1626
August 19, 2005**

Case Serial Number: 10/633083

**From: Kathleen Fuller
Location: EIC 1700
REMSEN 4B28
Phone: 571/272-2505
Kathleen.Fuller@uspto.gov**

Search Notes

SEARCH REQUEST FORM

Access DB# 161887

Scientific and Technical Information Center

Requester's Full Name: BEN SACKET Examiner #: 73489 Date: 8/6/05
 Art Unit: 1626 Phone Number 302-0704 Serial Number: 10/633/2R3
 Mail Box and Bldg/Room Location: Rem 5B3 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.


 Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: 1,2,4 triazole Derivative

Inventors (please provide full names): Hwan Cho et al.

Earliest Priority Filing Date: 11/26/02

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.



1 is naphthyl, indolyl etc.

2 is methyl, or amino

3, B, C and D are each carbon or nitrogen

TAFF USE ONLY

Searcher: K. Fuller
 Searcher Phone #: _____
 Searcher Location: _____
 Date Searcher Picked Up: _____
 Date Completed: 8/19/05
 Searcher Prep & Review Time: 20
 Technical Prep Time: _____
 Review Time: 20
 J-1590 (8-01) subset

Type of Search

NA Sequence (#) _____
 AA Sequence (#) _____
 Structure (#) 2
 Bibliographic _____
 Litigation _____
 Fulltext _____
 Patent Family _____
 Other _____

Vendors and cost where applicable

STN ✓
 Dialog _____
 Questel/Orbit _____
 Dr.Link _____
 Lexis/Nexis _____
 Sequence Systems _____
 WWW/Internet _____
 Other (specify) _____

=> FILE REG

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 2.45 | 224.65 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|--|------------------|---------------|
| CA SUBSCRIBER PRICE | 0.00 | -0.73 |

FILE 'REGISTRY' ENTERED AT 15:29:17 ON 19 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 AUG 2005 HIGHEST RN 860995-12-6
DICTIONARY FILE UPDATES: 18 AUG 2005 HIGHEST RN 860995-12-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> FILE HCAPLUS

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 0.43 | 225.08 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|--|------------------|---------------|
| CA SUBSCRIBER PRICE | 0.00 | -0.73 |

FILE 'HCAPLUS' ENTERED AT 15:29:21 ON 19 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


FILE COVERS 1907 - 19 Aug 2005 VOL 143 ISS 9
FILE LAST UPDATED: 18 Aug 2005 (20050818/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> D QUE
L3

STR




333 structures from query

VAR G1=C/N
VAR G2=N/AK
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L5 333 SEA FILE=REGISTRY SSS FUL L3
L7 STR



*Subset search to get rid
of phenyl rings at
this position*

*46 structures with rings
other than phenyl*

VAR G1=C/N
VAR G2=N/AK
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY UNS AT 16
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

L9 287 SEA FILE=REGISTRY SUB=L5 SSS FUL L7
L10 46 SEA FILE=REGISTRY ABB=ON L5 NOT L9
L11 5 SEA FILE=HCAPLUS ABB=ON L10
L12 5 SEA FILE=HCAPLUS ABB=ON L11(L) PREP/RL

5 CA references

=> D L12 1-5 BIB ABS IND HITSTR

L12 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:453194 HCAPLUS
DN 141:7124
TI Preparation of 1,2,4-triazoles as Cyclooxygenase-2 (COX-2) inhibitors for
treating fever, pain and inflammation
IN Cho, Il-hwan; Ko, Dong-hyun; Chae, Myeong-yun; Kim, Tae-rho; Kang,
Kyoung-rae; Kim, Jong-hoon; Jung, Sung-hak; Park, Sang-wook; Chun,
Hyung-ok; Ryu, Hyung-chul; Noh, Ji-young; Park, Hyun-jung; Park, Jie-eun;
Chung, Young-mee
PA CJ Corporation, S. Korea
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2004046121 | A1 | 20040603 | WO 2003-KR1514 | 20030729 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, | | | | |

PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 6849652 B1 20050201 US 2003-631594 20030731
PRAI KR 2002-72688 A 20021121
OS MARPAT 141:7124
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein Ar = naphthyl, 3,4-methylenedioxyphenyl,
(un)substituted Ph; and their non-toxic salts] were prepared as
Cyclooxygenase-2 (COX-2) inhibitors for treating fever, pain and
inflammation. For example, II was prepared by cyclocondensation of
acetamidrazone III with benzoyl chloride in Py, and oxidation with MMPP in
CH₂Cl₂. % Inhibition ratios of COX-2 to COX-1 for compds. I were
significantly higher than that in Valdecocixib. Thus, I are useful for
treating fever, pain, inflammation, neoplasm, and dementia.

IC ICM C07D249-08
ICS A61K031-4196; A61P029-00

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

ST triazole prepn cyclooxygenase COX2 inhibitor fever pain inflammation
neoplasm; dementia analgesic antiinflammatory antipyretic triazole prepn
COX2 inhibitor

IT Mental disorder
(dementia; preparation of triazoles as selective COX-2 inhibitors for
treating fever, pain and inflammation)

IT Analgesics
Anti-inflammatory agents
Antipyretics
Antitumor agents
Fever and Hyperthermia
Human
Inflammation
Neoplasm
Pain
(preparation of triazoles as selective COX-2 inhibitors for treating fever,
pain and inflammation)

IT 696602-82-1P, 1-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-phenyl-3-
trifluoromethyl-1H-1,2,4-triazole 696602-89-8P, 1-[3-Fluoro-4-
(methanesulfonyl)phenyl]-5-(4-methoxyphenyl)-3-trifluoromethyl-1H-1,2,4-
triazole 696602-96-7P, 1-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-(4-
fluorophenyl)-3-trifluoromethyl-1H-1,2,4-triazole 696603-03-9P,
1-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-(4-bromophenyl)-3-trifluoromethyl-
1H-1,2,4-triazole 696603-09-5P, 1-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-
(4-chlorophenyl)-3-trifluoromethyl-1H-1,2,4-triazole 696603-17-5P,
1-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-(4-methylphenyl)-3-
trifluoromethyl-1H-1,2,4-triazole 696603-24-4P, 1-[3-Fluoro-4-
(methanesulfonyl)phenyl]-5-(4-ethoxyphenyl)-3-trifluoromethyl-1H-1,2,4-
triazole 696603-32-4P, 1-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-(3-
chlorophenyl)-3-trifluoromethyl-1H-1,2,4-triazole 696603-41-5P,
1-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-(3-fluorophenyl)-3-
trifluoromethyl-1H-1,2,4-triazole 696603-48-2P, 1-[3-Fluoro-4-

(methanesulfonyl)phenyl]-5-(3-fluoro-4-methoxyphenyl)-3-trifluoromethyl-1H-1,2,4-triazole 696603-54-0P, 1-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-(3-methylphenyl)-3-trifluoromethyl-1H-1,2,4-triazole 696603-61-9P, 1-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-(naphthalen-2-yl)-3-trifluoromethyl-1H-1,2,4-triazole 696603-69-7P, 5-([1,3]Benzodioxol-5-yl)-1-[3-fluoro-4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-1,2,4-triazole 696603-74-4P, 1-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-(3,4-difluorophenyl)-3-trifluoromethyl-1H-1,2,4-triazole

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation);

USES (Uses)

(COX-2 inhibitor; preparation of triazoles as selective COX-2 inhibitors for treating fever, pain and inflammation)

IT 329900-75-6, COX-2 329967-85-3, COX-1

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibition; preparation of triazoles as selective COX-2 inhibitors for treating fever, pain and inflammation)

IT 20901-69-3P, (3-Fluoro-4-methylsulfonylphenyl)amine 252561-32-3P,

[3-Fluoro-4-(methanesulfonyl)phenyl]hydrazine hydrochloride

252561-33-4P, 3-Fluoro-4-(methanesulfonyl)nitrobenzene 252561-34-5P,

(3-Fluoro-4-methylsulfonylphenyl)amine 372121-91-0P,

3-Fluoro-4-methylsulfonylnitrobenzene 696601-40-8P, 3-Fluoro-4-

methylsulfonylphenylhydrazine 696601-46-4P, N-(3-Fluoro-4-

methylsulfonylphenyl)trifluoroacetamidrazone 696601-76-0P,

N-[3-Fluoro-4-(methanesulfonyl)phenyl]trifluoroacetamidrazone

696601-83-9P, 1-(3-Fluoro-4-methylsulfonylphenyl)-5-phenyl-3-

trifluoromethyl-1H-1,2,4-triazole 696601-92-0P, 1-(3-Fluoro-4-

methylsulfonylphenyl)-5-(4-methoxyphenyl)-3-trifluoromethyl-1H-1,2,4-

triazole 696602-03-6P, 1-(3-Fluoro-4-methylsulfonylphenyl)-5-(4-

fluorophenyl)-3-trifluoromethyl-1H-1,2,4-triazole 696602-14-9P,

1-(3-Fluoro-4-methylsulfonylphenyl)-5-(4-bromophenyl)-3-trifluoromethyl-1H-

1,2,4-triazole 696602-21-8P, 1-(3-Fluoro-4-methylsulfonylphenyl)-5-(4-

chlorophenyl)-3-trifluoromethyl-1H-1,2,4-triazole 696602-29-6P,

1-(3-Fluoro-4-methylsulfonylphenyl)-5-(4-methylphenyl)-3-trifluoromethyl-

1H-1,2,4-triazole 696602-36-5P, 1-(3-Fluoro-4-methylsulfonylphenyl)-5-(4-

ethoxyphenyl)-3-trifluoromethyl-1H-1,2,4-triazole 696602-43-4P,

1-(3-Fluoro-4-methylsulfonylphenyl)-5-(3-chlorophenyl)-3-trifluoromethyl-

1H-1,2,4-triazole 696602-49-0P, 1-(3-Fluoro-4-methylsulfonylphenyl)-5-(3-

fluorophenyl)-3-trifluoromethyl-1H-1,2,4-triazole 696602-53-6P,

1-(3-Fluoro-4-methylsulfonylphenyl)-5-(3-fluoro-4-methoxyphenyl)-3-

trifluoromethyl-1H-1,2,4-triazole 696602-59-2P, 1-(3-Fluoro-4-

methylsulfonylphenyl)-5-(3-methylphenyl)-3-trifluoromethyl-1H-1,2,4-

triazole 696602-68-3P, 1-(3-Fluoro-4-methylsulfonylphenyl)-5-(naphthalen-

2-yl)-3-trifluoromethyl-1H-1,2,4-triazole 696602-75-2P,

5-([1,3]Benzodioxol-5-yl)-1-(3-fluoro-4-methylsulfonylphenyl)-3-

trifluoromethyl-1H-1,2,4-triazole

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of triazoles as selective COX-2 inhibitors for treating fever, pain and inflammation)

IT 100-07-2, 4-Methoxybenzoyl chloride 122-01-0, 4-Chlorobenzoyl chloride

369-34-6, 3,4-Difluoronitrobenzene 403-43-0, 4-Fluorobenzoyl chloride

586-75-4, 4-Bromobenzoyl chloride 618-46-2, 3-Chlorobenzoyl chloride

874-60-2, 4-Methylbenzoyl chloride 1711-06-4, 3-Methylbenzoyl chloride

1711-07-5, 3-Fluorobenzoyl chloride 2243-83-6, Naphthalene-2-carbonyl

chloride 3907-15-1, 3-Fluoro-4-methoxybenzoyl chloride 16331-46-7,

4-Ethoxybenzoyl chloride 25054-53-9, [1,3]Benzodioxole-5-carbonyl

chloride 696603-81-3, 1-(3-Fluoro-4-methylsulfonylphenyl)-5-(3,4-

difluorophenyl)-3-trifluoromethyl-1H-1,2,4-triazole

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of triazoles as selective COX-2 inhibitors for treating fever, pain and inflammation)

IT 696603-61-9P, 1-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-(naphthalen-2-yl)-3-trifluoromethyl-1H-1,2,4-triazole 696603-69-7P, 5-([1,3]Benzodioxol-5-yl)-1-[3-fluoro-4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-1,2,4-triazole


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation);

USES (Uses)

(COX-2 inhibitor; preparation of triazoles as selective COX-2 inhibitors for treating fever, pain and inflammation)


RN 696603-61-9 HCAPLUS

CN 1H-1,2,4-Triazole, 1-[3-fluoro-4-(methylsulfonyl)phenyl]-5-(2-naphthalenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 696603-69-7 HCAPLUS

CN 1H-1,2,4-Triazole, 5-(1,3-benzodioxol-5-yl)-1-[3-fluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L12 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:451632 HCAPLUS

DN 141:23536

TI Preparation of 1,2,4-triazole derivatives as selective COX-2 inhibitors

IN Cho, Il Hwan; Ko, Dong Hyun; Chae, Myeong Yun; Kim, Taerho; Kang, Kyoung
Rae; Kim, Jong Hoon; Jung, Sung Hak; Park, Sang Wook; Chun, Hyung Ok; Ryu,
Hyung Chul; Noh, Ji Young; Park, Hyun Jung; Park, Jie Eun; Chung, Young
Mee

PA S. Korea

SO U.S. Pat. Appl. Publ., 13 pp.


CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | US 2004106612 | A1 | 20040603 | US 2003-633083 | 20030801 |
| | WO 2004048367 | A1 | 20040610 | WO 2003-KR1530 | 20030730 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| PRAI | KR 2002-74118 | A | 20021126 | | |
| OS | MARPAT 141:23536 | | | | |
| GI | | | | | |



AB The title compds. [I; R1 = (un)substituted naphthyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzothiazolyl, benzotriazolyl, benzooxazolyl, quinolinyl, isoquinolinyl; R2 = Me, NH2; A, B, C, D = C, N] which showed selective inhibition of COX-2 to COX-1, were prepared E.g., a 3-step synthesis of I [R1 = 2-naphthyl; R2 = Me; A, B, C, D = CH], starting from 4-methylsulfanylphenylhydrazine.HCl and trifluoroacetimidine, which showed 12.3% COX-2 inhibition at 10 nM vs. 26.2% COX-1 inhibition at 1 μ M, was given.

IC ICM A61K031-53
ICS A61K031-513; A61K031-501; A61K031-497; A61K031-4439; A61K031-4196

INCL 514241000; 514252050; 514255050; 514269000; 514341000; 514383000;
544182000; 544238000; 544405000; 546272400

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

ST triazole prepn prostaglandin endoperoxide synthetase COX2 inhibitor

IT 329900-75-6, COX-2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(COX-2; preparation of 1,2,4-triazole derivs. as selective COX-2 inhibitors)

IT 698350-38-8P 698350-39-9P 698350-40-2P
698350-41-3P 698350-42-4P 698350-43-5P

698350-44-6P 698350-45-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); **PREP (Preparation)**;
USES (Uses)

(preparation of 1,2,4-triazole derivs. as selective COX-2 inhibitors)

IT 354-37-0, Trifluoroacetamide 2243-83-6, 2-Naphthoyl chloride
41717-28-6, Benzofuran-2-carbonyl chloride 50342-01-3,
Quinoline-2-carbonyl chloride 58626-97-4 58881-45-1,
1H-Indole-2-carbonyl chloride 118618-61-4, 1-Methyl-1H-indole-2-carbonyl
chloride 126921-19-5 343262-52-2 343338-96-5 481052-73-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 1,2,4-triazole derivs. as selective COX-2 inhibitors)

IT 481649-93-8P 660400-36-2P 660400-37-3P 698350-32-2P 698350-33-3P
698350-34-4P 698350-35-5P 698350-36-6P 698350-37-7P

RL: RCT (Reactant); SPN (Synthetic preparation); **PREP (Preparation)**; RACT
(Reactant or reagent)

(preparation of 1,2,4-triazole derivs. as selective COX-2 inhibitors)


IT **698350-38-8P 698350-39-9P 698350-40-2P**
698350-41-3P 698350-42-4P 698350-43-5P
698350-44-6P 698350-45-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); **PREP (Preparation)**;
USES (Uses)

(preparation of 1,2,4-triazazole derivs. as selective COX-2 inhibitors)


RN 698350-38-8 HCAPLUS

CN 1H-1,2,4-Triazole, 1-[4-(methylsulfonyl)phenyl]-5-(2-naphthalenyl)-3-
(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 698350-39-9 HCAPLUS

CN 1H-1,2,4-Triazole, 5-(2-benzofuranyl)-1-[4-(methylsulfonyl)phenyl]-3-
(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 698350-40-2 HCAPLUS

CN 1H-Indole, 2-[1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl]- (9CI) (CA INDEX NAME)




RN 698350-41-3 HCAPLUS

CN 1H-Indole, 1-methyl-2-[1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl]- (9CI) (CA INDEX NAME)




RN 698350-42-4 HCAPLUS

CN 1H-Indole, 1-methyl-3-[1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl]- (9CI) (CA INDEX NAME)




RN 698350-43-5 HCAPLUS

CN Quinoline, 2-[1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl]- (9CI) (CA INDEX NAME)




RN 698350-44-6 HCAPLUS

CN Benzenesulfonamide, 4-[5-(2-naphthalenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 698350-45-7 HCAPLUS

CN Pyridine, 5-(methylsulfonyl)-2-[5-(2-naphthalenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



L12 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:143123 HCAPLUS

DN 140:181455

TI Preparation of 1-(hetero)aryl-3-trifluoromethyl-1H-1,2,4-triazoles as cyclooxygenase-2 selective inhibitors

IN Cho, Il-hwan; Park, Hyun-jung; Noh, Ji-young; Ryu, Hyung-chul; Park, Sang-wook; Jung, Sung-hak; Lee, Sung-hak; Kim, Jong-hoon; Lim, Jee-woong; Lyu, Chun-seon; Kim, Dal-hyun; Kim, Young-hoon; Yeon, Kyu-jeong; Chae, Myeong-yun; Min, In-ki; Jin, Hae-tak; Kang, Kyoung-rae

PA Cj Corporation, S. Korea

SO PCT Int. Appl., 105 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004014878 | A1 | 20040219 | WO 2003-KR1183 | 20030617 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2494321 | AA | 20040219 | CA 2003-2494321 | 20030617 |
| | EP 1539718 | A1 | 20050615 | EP 2003-784655 | 20030617 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | US 2005075507 | A1 | 20050407 | US 2003-608709 | 20030627 |
| PRAI | KR 2002-46551 | A | 20020807 | | |
| | WO 2003-KR1183 | W | 20030617 | | |
| OS | MARPAT 140:181455 | | | | |
| GI | | | | | |



AB Title amidrazone derivs. I [wherein R1 = cycloalkyl, cycloalkenyl, (un)substituted Ph, (alkoxy)styrenyl, or pyridyl; R2 = Me or NH2; A, B, C, and D = independently C or N; or a nontoxic salt thereof] were prepared as cyclooxygenase-2 (COX-2) selective inhibitors. For example, oxidation of 5-(4-ethoxyphenyl)-1-(4-methylsulfonylphenyl)-3-trifluoromethyl-1H-[1,2,4]triazole using 80% MMPP in CH2Cl2 gave the methanesulfonylphenyl derivative II (82%). The latter selectively inhibited COX-2 (38.65%) to COX-1 (11.8%). In addition, II suppressed carrageenan-induced paw edema in rats by 32.3%, compared to 23.9% suppression by the celecoxib reference. Thus, I and their pharmaceutical compns. are useful in the treatment of fever, pain, inflammation, cancer, and dementia (no data).

IC ICM C07D249-08

ICS A61P029-00

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

ST triazole amidrazone deriv prepn cyclooxygenase COX2 inhibitor; fever pain inflammation cancer dementia treatment triazole prepn

IT Mental disorder

(dementia; preparation of triazoles as COX-2 inhibitors for treatment of fever, pain, inflammation, cancer, and dementia)

IT Analgesics

Anti-inflammatory agents

Antipyretics

Antitumor agents

Drug delivery systems

Fever and Hyperthermia

Human

Inflammation

Neoplasm

Pain

(preparation of triazoles as COX-2 inhibitors for treatment of fever, pain, inflammation, cancer, and dementia)

IT 481052-73-7P 481649-93-8P 660400-36-2P 660400-37-3P 660400-38-4P
660400-40-8P 660400-41-9P, 1-[4-(Methylsulfonyl)phenyl]-5-phenyl-3-trifluoromethyl-1H-[1,2,4]triazole 660400-42-0P, 5-(4-Chlorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660400-43-1P, 5-(4-Bromophenyl)-1-[4-(methylsulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-44-2P, 1-[4-(Methylsulfonyl)phenyl]-5-(4-methoxyphenyl)-3-trifluoromethyl-1H-[1,2,4]triazole 660400-45-3P, 5-(3-Bromophenyl)-1-[4-(methylsulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660400-46-4P, 5-(3-Chlorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-47-5P, 5-(3-Trifluoromethylphenyl)-1-[4-(methylsulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-48-6P, 5-(2,4-Dimethoxyphenyl)-1-[4-(methylsulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole

660400-49-7P, 5-Styryl-1-[4-(methylsulfanyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-50-0P, 5-[2-(4-Methoxyphenyl)vinyl]-1-[4-(methylsulfanyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660400-51-1P, 5-(4-Ethoxyphenyl)-1-[4-(methylsulfanyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-52-2P, 5-(4-tert-Butylphenyl)-1-[4-(methylsulfanyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660400-53-3P, 5-(4-Cyanophenyl)-1-[4-(methylsulfanyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-54-4P, 5-(4-Nitro-2-chlorophenyl)-1-[4-(methylsulfanyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660400-55-5P, 5-(3-Chloro-4-methoxyphenyl)-1-[4-(methylsulfanyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660400-56-6P, 5-(Benzodioxol-5-yl)-1-[4-(methylsulfanyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-57-7P, 4-[2-[4-(Methylsulfanyl)phenyl]-5-trifluoromethyl-2H-[1,2,4]triazol-3-yl]pyridine
660400-58-8P, 1-[4-(Methanesulfonyl)phenyl]-5-(p-tolyl)-3-trifluoromethyl-1H-[1,2,4]triazole

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(COX inhibitor; preparation of triazoles as COX-2 inhibitors for treatment of fever, pain, inflammation, cancer, and dementia)

IT 481052-74-8P, 4-(5-Phenyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfonamide 481052-76-0P, 4-[5-(Pyridin-3-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 481052-81-7P, 4-[5-(4-Fluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 481052-87-3P, 4-(5-Cyclohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfonamide 481649-84-7P, 6-(5-Phenyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine-3-sulfonic acid amide 481649-86-9P, 6-[5-(Pyridin-3-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 481649-87-0P, 6-[5-(Pyridin-4-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 481649-89-2P, 6-[5-(4-Fluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 481649-91-6P, 6-(5-Cyclohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine-3-sulfonic acid amide 660400-59-9P, 1-[4-(Methanesulfonyl)phenyl]-5-phenyl-3-trifluoromethyl-1H-[1,2,4]triazole
660400-60-2P, 5-(4-Chlorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-61-3P, 5-(4-Bromophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660400-62-4P, 1-[4-(Methanesulfonyl)phenyl]-5-(4-methoxyphenyl)-3-trifluoromethyl-1H-[1,2,4]triazole 660400-63-5P, 5-(3-Bromophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660400-64-6P, 5-(3-Chlorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-65-7P, 5-(3-Trifluoromethylphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-66-8P, 5-(2,4-Dimethoxyphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660400-67-9P, 5-Styryl-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-68-0P, 5-[2-(4-Methoxyphenyl)vinyl]-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660400-69-1P, 5-(4-Ethoxyphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-70-4P, 5-(4-tert-Butylphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660400-71-5P, 5-(4-Cyanophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-72-6P, 5-(4-Nitro-2-chlorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660400-73-7P, 5-(3-Chloro-4-methoxyphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660400-74-8P, 5-(Benzodioxol-5-yl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-75-9P,

4-[2-[4-(Methanesulfonyl)phenyl]-5-trifluoromethyl-2H-[1,2,4]triazol-3-yl]pyridine 660400-76-0P, 4-[5-(p-Tolyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 660400-77-1P, 4-[5-(4-Methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 660400-78-2P 660400-79-3P, 2-[5-(4-Bromophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-(methanesulfonyl)pyridine 660400-80-6P, 2-[5-(4-Methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-(methanesulfonyl)pyridine 660400-81-7P, 2-(Methanesulfonyl)-5-[5-(4-bromophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine 660400-82-8P 660400-83-9P, 3-[5-(4-Bromophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-6-(methanesulfonyl)pyridazine 660400-84-0P, 3-[5-(4-Methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-6-(methanesulfonyl)pyridazine 660400-85-1P, 5-(4-Fluorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-86-2P, 5-(3,5-Dichloro-4-methoxyphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-87-3P, 5-(3,4-Dichlorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-88-4P, 5-(3,4-Dimethoxyphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-89-5P, 5-(3,4-Difluorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-90-8P, 5-(3,4-Dimethylphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-91-9P, 5-(3-Chloro-4-methylphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-92-0P, 5-(4-Chloro-3-methylphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-93-1P, 5-(4-Chloro-3-methoxyphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-94-2P, 5-(3-Fluoro-4-methylphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-95-3P, 5-(4-Fluoro-3-methylphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-96-4P, 5-(3-Fluoro-4-methoxyphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-97-5P, 1-[4-(Methanesulfonyl)phenyl]-3-trifluoromethyl-5-(4-trifluoromethylphenyl)-1H-[1,2,4]triazole 660400-98-6P, 1-[4-(Methanesulfonyl)phenyl]-5-(4-trifluoromethoxyphenyl)-3-trifluoromethyl-1H-[1,2,4]triazole 660400-99-7P, 5-[4-(N-Methylamino)phenyl]-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660401-00-3P, 5-[4-(N,N-Dimethylamino)phenyl]-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660401-01-4P, 5-(4-Aminophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660401-02-5P, 5-(3-Methoxyphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660401-03-6P, 1-[4-(Methanesulfonyl)phenyl]-5-(m-tolyl)-3-trifluoromethyl-1H-[1,2,4]triazole 660401-04-7P, 1-[4-(Methanesulfonyl)phenyl]-5-(o-tolyl)-3-trifluoromethyl-1H-[1,2,4]triazole 660401-05-8P, 5-(2-Bromophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660401-06-9P, 5-(2-Methoxyphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660401-07-0P, 5-(2,4-Difluorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660401-08-1P, 5-(2,5-Difluorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660401-09-2P, 5-(2,4,5-Trifluorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660401-10-5P, 5-(2,3-Dichlorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660401-11-6P, 5-(2,4-Dichlorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660401-12-7P, 5-(3,5-Difluorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660401-13-8P, 5-(3,5-Dimethoxyphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660401-14-9P, 5-(3,4,5-Trimethoxyphenyl)-1-[4-(methanesulfonyl)phenyl]-3-

trifluoromethyl-1H-[1,2,4]triazole 660401-15-0P, 5-(2-Fluoro-4-trifluoromethylphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660401-16-1P, 5-(2,4-Dichloro-5-fluorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660401-17-2P, 5-(Methanesulfonyl)-2-[3-trifluoromethyl-5-(4-trifluoromethylphenyl)-[1,2,4]triazol-1-yl]pyridine 660401-18-3P, 5-(Methanesulfonyl)-2-[3-trifluoromethyl-5-(4-ethoxyphenyl)-[1,2,4]triazol-1-yl]pyridine 660401-19-4P, 5-(Methanesulfonyl)-2-[3-trifluoromethyl-5-(4-trifluoromethoxyphenyl)-[1,2,4]triazol-1-yl]pyridine 660401-20-7P, 5-(Methanesulfonyl)-2-[3-trifluoromethyl-5-(4-tert-butylphenyl)-[1,2,4]triazol-1-yl]pyridine 660401-21-8P, 5-(Methanesulfonyl)-2-[3-trifluoromethyl-5-(4-cyanophenyl)-[1,2,4]triazol-1-yl]pyridine 660401-22-9P, 5-(Methanesulfonyl)-2-[3-trifluoromethyl-5-(4-aminophenyl)-[1,2,4]triazol-1-yl]pyridine 660401-23-0P 660401-24-1P, 5-(Methanesulfonyl)-2-[3-trifluoromethyl-5-[4-(dimethylamino)phenyl]-[1,2,4]triazol-1-yl]pyridine 660401-25-2P, 5-(Methanesulfonyl)-2-[3-trifluoromethyl-5-(3-methylphenyl)-[1,2,4]triazol-1-yl]pyridine 660401-26-3P, 5-(Methanesulfonyl)-2-[3-trifluoromethyl-5-(3-trifluoromethylphenyl)-[1,2,4]triazol-1-yl]pyridine 660401-27-4P, 5-(Methanesulfonyl)-2-[3-trifluoromethyl-5-(3-methoxyphenyl)-[1,2,4]triazol-1-yl]pyridine 660401-28-5P, 5-(Methanesulfonyl)-2-[3-trifluoromethyl-5-(2,4-difluorophenyl)-[1,2,4]triazol-1-yl]pyridine 660401-29-6P, 5-(Methanesulfonyl)-2-[3-trifluoromethyl-5-(2,5-difluorophenyl)-[1,2,4]triazol-1-yl]pyridine 660401-30-9P, 5-(Methanesulfonyl)-2-[3-trifluoromethyl-5-(2,4,5-trifluorophenyl)-[1,2,4]triazol-1-yl]pyridine 660401-31-0P, 5-(Methanesulfonyl)-2-[3-trifluoromethyl-5-(2,3-dichlorophenyl)-[1,2,4]triazol-1-yl]pyridine 660401-32-1P, 5-(Methanesulfonyl)-2-[3-trifluoromethyl-5-(2,4-dichlorophenyl)-[1,2,4]triazol-1-yl]pyridine 660401-33-2P, 5-(Methanesulfonyl)-2-[3-trifluoromethyl-5-(3,5-difluorophenyl)-[1,2,4]triazol-1-yl]pyridine 660401-34-3P, 5-(Methanesulfonyl)-2-[3-trifluoromethyl-5-(3,5-dimethoxyphenyl)-[1,2,4]triazol-1-yl]pyridine 660401-35-4P, 5-(Methanesulfonyl)-2-[3-trifluoromethyl-5-(2,4-dimethoxyphenyl)-[1,2,4]triazol-1-yl]pyridine 660401-36-5P, 5-(Methanesulfonyl)-2-[3-trifluoromethyl-5-(3,4,5-trifluorophenyl)-[1,2,4]triazol-1-yl]pyridine 660401-37-6P, 5-(Methanesulfonyl)-2-[3-trifluoromethyl-5-(2-fluoro-4-trifluoromethylphenyl)-[1,2,4]triazol-1-yl]pyridine 660401-38-7P, 5-(Methanesulfonyl)-2-[3-trifluoromethyl-5-(2-chloro-4-nitrophenyl)-[1,2,4]triazol-1-yl]pyridine 660401-39-8P, 5-(Methanesulfonyl)-2-[3-trifluoromethyl-5-(2,4-dichloro-5-fluorophenyl)-[1,2,4]triazol-1-yl]pyridine 660401-40-1P, 5-(Methanesulfonyl)-2-[3-trifluoromethyl-5-(3-fluoro-4-methylphenyl)-[1,2,4]triazol-1-yl]pyridine 660401-41-2P, 2-[5-(Benzodioxol-5-yl)-3-trifluoromethyl-1,2,4]triazol-1-yl]-5-(methanesulfonyl)pyridine 660401-42-3P, 3-[2-[4-(Methanesulfonyl)phenyl]-5-trifluoromethyl-2H-[1,2,4]triazol-3-yl]pyridine 660401-43-4P, 5-Cyclohexyl-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660401-44-5P, 5-Cyclohexen-1-yl-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660401-45-6P, 4-[5-(3,4-Difluorophenyl)-3-trifluoromethyl-1,2,4]triazol-1-yl]benzenesulfonamide 660401-46-7P, 4-[5-(4-Chlorophenyl)-3-trifluoromethyl-1,2,4]triazol-1-yl]benzenesulfonamide 660401-47-8P, 4-[5-(3,4-Dichlorophenyl)-3-trifluoromethyl-1,2,4]triazol-1-yl]benzenesulfonamide 660401-48-9P, 4-[5-(3,4-Dimethoxyphenyl)-3-trifluoromethyl-1,2,4]triazol-1-yl]benzenesulfonamide 660401-49-0P, 4-[5-(3,4-Dimethylphenyl)-3-trifluoromethyl-1,2,4]triazol-1-yl]benzenesulfonamide 660401-50-3P, 4-[5-(3-Chloro-4-methylphenyl)-3-trifluoromethyl-1,2,4]triazol-1-yl]benzenesulfonamide 660401-51-4P, 4-[5-(4-Chloro-3-methylphenyl)-3-trifluoromethyl-1,2,4]triazol-1-yl]benzenesulfonamide 660401-52-5P, 4-[5-(3-Chloro-4-methoxyphenyl)-3-trifluoromethyl-1,2,4]triazol-1-

yl]benzenesulfonamide 660401-53-6P, 4-[5-(4-Chloro-3-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-54-7P, 4-[5-(3-Fluoro-4-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-55-8P, 4-[5-(4-Fluoro-3-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-56-9P, 4-[5-(3-Fluoro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-57-0P, 4-[5-(3,5-Dichloro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-58-1P, 4-[3-Trifluoromethyl-5-(4-trifluoromethylphenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-59-2P, 4-[3-Trifluoromethyl-5-(4-ethoxyphenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-60-5P, 4-[3-Trifluoromethyl-5-(4-trifluoromethoxyphenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-61-6P, 4-[3-Trifluoromethyl-5-(4-tert-butylphenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-62-7P, 4-[3-Trifluoromethyl-5-(4-cyanophenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-63-8P, 4-[3-Trifluoromethyl-5-(4-aminophenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-64-9P, 660401-65-0P, 4-[3-Trifluoromethyl-5-[4-(dimethylamino)phenyl]-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-66-1P, 4-[3-Trifluoromethyl-5-(m-tolyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-67-2P, 4-[3-Trifluoromethyl-5-(3-trifluoromethylphenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-68-3P, 4-[3-Trifluoromethyl-5-(3-methoxyphenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-69-4P, 4-[3-Trifluoromethyl-5-(2-bromophenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-70-7P, 4-[3-Trifluoromethyl-5-(2-methoxyphenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-71-8P, 4-[3-Trifluoromethyl-5-(2,4-difluorophenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-72-9P, 4-[3-Trifluoromethyl-5-(2,5-difluorophenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-73-0P, 4-[3-Trifluoromethyl-5-(2,4,5-trifluorophenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-74-1P, 4-[3-Trifluoromethyl-5-(2,3-dichlorophenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-75-2P, 4-[3-Trifluoromethyl-5-(2,4-dichlorophenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-76-3P, 4-[3-Trifluoromethyl-5-(3,5-dimethoxyphenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-77-4P, 4-[3-Trifluoromethyl-5-(2,4-dimethoxyphenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-78-5P, 4-[3-Trifluoromethyl-5-(3,4,5-trifluorophenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-79-6P, 4-[3-Trifluoromethyl-5-(2-fluoro-4-trifluoromethylphenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-80-9P, 4-[3-Trifluoromethyl-5-(2-chloro-4-nitrophenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-81-0P, 4-[3-Trifluoromethyl-5-(2,4-dichloro-5-fluorophenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-82-1P, 4-[5-(Benzodioxol-5-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-83-2P, 4-[5-(Pyridin-4-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-84-3P 660401-85-4P, 5-(Methanesulfonyl)-2-(5-phenyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine 660401-86-5P, 2-[5-(4-Fluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-(methanesulfonyl)pyridine 660401-87-6P, 2-[5-(3,4-Difluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-(methanesulfonyl)pyridine 660401-88-7P, 2-[5-(4-Chlorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-(methanesulfonyl)pyridine 660401-89-8P, 2-[5-(3,4-Dichlorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-(methanesulfonyl)pyridine 660401-90-1P, 2-[5-(3,4-Dimethoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-(methanesulfonyl)pyridine 660401-91-2P, 5-(Methanesulfonyl)-2-[5-(p-tolyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine 660401-92-3P, 2-[5-(3,4-Dimethylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-(methanesulfonyl)pyridine 660401-93-4P, 2-[5-(3-Chloro-4-methylphenyl)-3-trifluoromethyl-

[1,2,4]triazol-1-yl]-5-(methanesulfonyl)pyridine 660401-94-5P,
2-[5-(4-Chloro-3-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-(methanesulfonyl)pyridine 660401-95-6P, 6-[5-(3-Chloro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660401-96-7P, 6-[5-(4-Chloro-3-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660401-97-8P, 6-[5-(3-Fluoro-4-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660401-98-9P, 6-[3-Trifluoromethyl-5-(4-trifluoromethylphenyl)-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660401-99-0P, 6-[3-Trifluoromethyl-5-(4-ethoxyphenyl)-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-00-6P, 6-[3-Trifluoromethyl-5-(4-trifluoromethoxyphenyl)-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-01-7P, 6-[3-Trifluoromethyl-5-(4-tert-butylphenyl)-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-02-8P, 6-[3-Trifluoromethyl-5-(4-cyanophenyl)-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-03-9P, 6-[3-Trifluoromethyl-5-(4-aminophenyl)-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-04-0P 660402-05-1P, 6-[3-Trifluoromethyl-5-[4-(dimethylamino)phenyl]-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-06-2P, 6-[3-Trifluoromethyl-5-(m-tolyl)-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-07-3P, 6-[3-Trifluoromethyl-5-(3-methoxyphenyl)-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-08-4P, 6-[3-Trifluoromethyl-5-(3-trifluoromethylphenyl)-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-09-5P, 6-[3-Trifluoromethyl-5-(2-bromophenyl)-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-10-8P, 6-[3-Trifluoromethyl-5-(2-methoxyphenyl)-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-11-9P, 6-[3-Trifluoromethyl-5-(2,4-difluorophenyl)-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-12-0P, 6-[3-Trifluoromethyl-5-(2,5-difluorophenyl)-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-13-1P, 6-[3-Trifluoromethyl-5-(3,5-difluorophenyl)-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-14-2P, 6-[3-Trifluoromethyl-5-(2,4,5-trifluorophenyl)-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-15-3P, 6-[3-Trifluoromethyl-5-(2-fluoro-4-trifluoromethylphenyl)-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-16-4P, 6-[3-Trifluoromethyl-5-(2,4-dimethoxyphenyl)-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-17-5P, 6-[3-Trifluoromethyl-5-(3,4,5-trimethoxyphenyl)-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-18-6P, 6-[3-Trifluoromethyl-5-(2-chloro-4-nitrophenyl)-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-19-7P, 2-[5-(4-Fluoro-3-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-(methanesulfonyl)pyridine 660402-20-0P, 2-[5-(3-Fluoro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-(methanesulfonyl)pyridine 660402-21-1P, 2-[5-(3,5-Dichloro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-(methanesulfonyl)pyridine 660402-22-2P, 5-(Methanesulfonyl)-2-[(3-pyridinyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine 660402-23-3P, 5-(Methanesulfonyl)-2-[(4-pyridinyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine 660402-24-4P, 2-(5-Cyclohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)-5-(methanesulfonyl)pyridine 660402-25-5P 660402-26-6P, 6-[5-(4-Bromophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-28-8P, 6-[5-(3,4-Difluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-30-2P, 6-[5-(4-Chlorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-32-4P, 6-[5-(3,4-Dichlorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-33-5P, 6-[5-(4-Methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-34-6P, 6-[5-(3,4-Dimethoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-35-7P, 6-[5-(p-Tolyl)-3-trifluoromethyl-

[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-36-8P,
6-[5-(3,4-Dimethylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-37-9P, 6-[5-(3-Chloro-4-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-38-0P, 6-[5-(4-Chloro-3-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-39-1P, 6-[5-(4-Fluoro-3-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-40-4P, 6-[5-(3-Fluoro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-41-5P, 6-[5-(3,5-Dichloro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 660402-42-6P 660402-43-7P, 2-(Methanesulfonyl)-5-(5-phenyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine 660402-44-8P, 5-[5-(4-Fluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-2-(methanesulfonyl)pyridine 660402-45-9P, 5-[5-(3,4-Difluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-2-(methanesulfonyl)pyridine 660402-46-0P, 5-[5-(4-Chlorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-2-(methanesulfonyl)pyridine 660402-47-1P, 5-[5-(3,4-Dichlorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-2-(methanesulfonyl)pyridine 660402-48-2P, 5-[5-(3,4-Dimethoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-2-(methanesulfonyl)pyridine 660402-49-3P, 2-(Methanesulfonyl)-5-[5-(p-tolyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine 660402-50-6P, 5-[5-(3,4-Dimethylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-2-(methanesulfonyl)pyridine 660402-51-7P, 5-[5-(3-Chloro-4-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-2-(methanesulfonyl)pyridine 660402-52-8P, 5-[5-(4-Chloro-3-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-2-(methanesulfonyl)pyridine 660402-53-9P, 5-[5-(3-Chloro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-2-pyridine-2-sulfonic acid amide 660402-54-0P, 5-[5-(4-Chloro-3-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-2-sulfonic acid amide 660402-55-1P, 5-[5-(3-Fluoro-4-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-2-sulfonic acid amide 660402-56-2P, 5-[5-(4-Fluoro-3-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-2-(methanesulfonyl)pyridine 660402-57-3P, 5-[5-(3-Fluoro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-2-(methanesulfonyl)pyridine 660402-58-4P, 5-[5-(3,5-Dichloro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-2-(methanesulfonyl)pyridine 660402-59-5P, 5-(5-Cyclohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)-2-(methanesulfonyl)pyridine 660402-60-8P 660402-61-9P, 5-(5-Phenyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine-2-sulfonic acid amide 660402-62-0P, 5-[5-(4-Bromophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-2-sulfonic acid amide 660402-63-1P, 5-[5-(4-Fluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-2-sulfonic acid amide 660402-64-2P, 5-[5-(3,4-Difluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-2-sulfonic acid amide 660402-65-3P, 5-[5-(4-Chlorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-2-sulfonic acid amide 660402-66-4P, 5-[5-(3,4-Dichlorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-2-sulfonic acid amide 660402-67-5P, 5-[5-(4-Methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-2-sulfonic acid amide 660402-68-6P, 5-[5-(3,4-Dimethoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-2-sulfonic acid amide 660402-69-7P, 5-[5-(p-Tolyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-2-sulfonic acid amide 660402-70-0P, 5-[5-(3,4-Dimethylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-2-sulfonic acid amide 660402-71-1P, 5-[5-(3-Chloro-4-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-2-sulfonic acid amide 660402-72-2P, 5-[5-(4-Chloro-3-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-2-sulfonic acid amide 660402-73-3P, 5-[5-(4-Fluoro-3-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-2-sulfonic acid amide 660402-74-4P,

5-[5-(3-Fluoro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-2-sulfonic acid amide 660402-75-5P, 5-[5-(3,5-Dichloro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-2-sulfonic acid amide 660402-76-6P, 5-[5-(Pyridin-3-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-2-sulfonic acid amide 660402-77-7P, 5-[5-(Pyridin-4-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-2-sulfonic acid amide 660402-78-8P, 5-(5-Cyclohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine-2-sulfonic acid amide 660402-79-9P 660402-80-2P, 3-(Methanesulfonyl)-6-(5-phenyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridazine 660402-81-3P, 3-[5-(4-Fluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-6-(methanesulfonyl)pyridazine 660402-82-4P, 3-[5-(3,4-Difluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-6-(methanesulfonyl)pyridazine 660402-83-5P, 3-[5-(4-Chlorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-6-(methanesulfonyl)pyridazine 660402-84-6P, 3-[5-(3,4-Dichlorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-6-(methanesulfonyl)pyridazine 660402-85-7P, 3-[5-(3,4-Dimethoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-6-(methanesulfonyl)pyridazine 660402-86-8P, 3-(Methanesulfonyl)-6-[5-(p-tolyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation);
USES (Uses)

(COX inhibitor; preparation of triazoles as COX-2 inhibitors for treatment of fever, pain, inflammation, cancer, and dementia)

IT 660402-87-9P, 3-[5-(3,4-Dimethylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-6-(methanesulfonyl)pyridazine 660402-88-0P, 3-[5-(3-Chloro-4-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-6-(methanesulfonyl)pyridazine 660402-89-1P, 3-[5-(4-Chloro-3-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-6-(methanesulfonyl)pyridazine 660402-90-4P, 3-[5-(3-Chloro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-6-(methanesulfonyl)pyridazine 660402-91-5P, 3-[5-(4-Chloro-3-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-6-(methanesulfonyl)pyridazine 660402-92-6P, 3-[5-(3-Fluoro-4-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-6-(methanesulfonyl)pyridazine 660402-93-7P, 3-[5-(4-Fluoro-3-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-6-(methanesulfonyl)pyridazine 660402-94-8P, 3-[5-(3-Fluoro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-6-(methanesulfonyl)pyridazine 660402-95-9P, 3-[5-(3,5-Dichloro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-6-(methanesulfonyl)pyridazine 660402-96-0P, 3-(Methanesulfonyl)-6-[5-(pyridin-3-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine 660402-97-1P, 3-(Methanesulfonyl)-6-[5-(pyridin-4-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine 660402-98-2P, 3-(5-Cyclohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)-6-(methanesulfonyl)pyridazine 660402-99-3P 660403-00-9P, 6-(5-Phenyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridazine-3-sulfonic acid amide 660403-01-0P, 6-[5-(4-Bromophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine-3-sulfonic acid amide 660403-02-1P, 6-[5-(4-Fluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine-3-sulfonic acid amide 660403-03-2P, 6-[5-(3,4-Difluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine-3-sulfonic acid amide 660403-04-3P, 6-[5-(4-Chlorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine-3-sulfonic acid amide 660403-05-4P, 6-[5-(3,4-Dichlorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine-3-sulfonic acid amide 660403-06-5P, 6-[5-(4-Methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine-3-sulfonic acid amide 660403-07-6P, 6-[5-(3,4-Dimethoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine-3-sulfonic acid amide 660403-08-7P, 6-[5-(p-Tolyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine-3-sulfonic acid amide 660403-09-8P, 6-[5-(3,4-Dimethylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-

yllpyridazine-3-sulfonic acid amide 660403-10-1P, 6-[5-(3-Chloro-4-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine-3-sulfonic acid amide 660403-11-2P, 6-[5-(4-Chloro-3-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine-3-sulfonic acid amide 660403-12-3P, 6-[5-(3-Chloro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine-3-sulfonic acid amide 660403-13-4P, 6-[5-(4-Chloro-3-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine-3-sulfonic acid amide 660403-14-5P, 6-[5-(3-Fluoro-4-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine-3-sulfonic acid amide 660403-15-6P, 6-[5-(4-Fluoro-3-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine-3-sulfonic acid amide 660403-16-7P, 6-[5-(3-Fluoro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine-3-sulfonic acid amide 660403-17-8P, 6-[5-(3,5-Dichloro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine-3-sulfonic acid amide 660403-18-9P, 6-[5-(Pyridin-3-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine-3-sulfonic acid amide 660403-19-0P, 6-[5-(Pyridin-4-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine-3-sulfonic acid amide 660403-20-3P, 6-(5-Cyclohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridazine-3-sulfonic acid amide 660403-21-4P 660403-22-5P, 5-(Methanesulfonyl)-2-(5-phenyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyrimidine 660403-23-6P 660403-24-7P 660403-25-8P 660403-26-9P 660403-27-0P 660403-28-1P 660403-29-2P 660403-30-5P 660403-31-6P 660403-32-7P 660403-33-8P 660403-34-9P 660403-35-0P 660403-36-1P 660403-37-2P 660403-38-3P 660403-39-4P 660403-40-7P 660403-41-8P 660403-42-9P 660403-43-0P 660403-44-1P 660403-45-2P 660403-46-3P 660403-47-4P 660403-48-5P 660403-49-6P 660403-50-9P 660403-51-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(COX inhibitor; preparation of triazoles as COX-2 inhibitors for treatment of fever, pain, inflammation, cancer, and dementia)

IT 100-07-2, p-Anisoyl chloride 102-92-1, Cinnamoyl chloride 122-01-0, 4-Chlorobenzoyl chloride 354-37-0 586-75-4, 4-Bromobenzoyl chloride 618-46-2, 3-Chlorobenzoyl chloride 874-60-2, p-Toluoyl chloride 1710-98-1, 4-tert-Butylbenzoyl chloride 1711-09-7, 3-Bromobenzoyl chloride 2251-65-2, 3-Trifluoromethylbenzoyl chloride 6068-72-0, 4-Cyanobenzoyl chloride 7073-36-1, 4-Nitro-2-chlorobenzoyl chloride 14254-57-0, Isonicotinoyl chloride 16331-46-7, 4-Ethoxybenzoyl chloride 25054-53-9, Benzodioxole-5-carbonyl chloride 27918-19-0, 4-Hydrazinobenzenesulfonamide hydrochloride 34446-64-5, 4-Methoxycinnamoyl chloride 36590-49-5, 3-Chloro-4-methoxybenzoyl chloride 39828-35-8, 2,4-Dimethoxybenzoyl chloride 58626-97-4 343262-52-2, [5-(Methanesulfonyl)pyridin-2-yl]hydrazine hydrochloride 343338-96-5, [2-(Methanesulfonyl)pyridin-5-yl]hydrazine hydrochloride 660400-39-5, [6-(Methanesulfonyl)pyridazin-3-yl]hydrazine hydrochloride

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of triazoles as COX-2 inhibitors for treatment of fever, pain, inflammation, cancer, and dementia)

IT 481052-76-0P, 4-[5-(Pyridin-3-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 481052-87-3P, 4-(5-Cyclohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfonamide 481649-86-9 P, 6-[5-(Pyridin-3-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 481649-87-0P, 6-[5-(Pyridin-4-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 481649-91-6P, 6-(5-Cyclohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine-3-sulfonic acid amide 660400-74-8P, 5-(Benzodioxol-5-yl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-75-9P, 4-[2-[4-(Methanesulfonyl)phenyl]-5-trifluoromethyl-2H-[1,2,4]triazol-3-yl]pyridine 660401-41-2P,


2-[5-(Benzodioxol-5-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-(methanesulfonyl)pyridine **660401-42-3P**, 3-[2-[4-(Methanesulfonyl)phenyl]-5-trifluoromethyl-2H-[1,2,4]triazol-3-yl]pyridine **660401-43-4P**, 5-Cyclohexyl-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole **660401-82-1P**, 4-[5-(Benzodioxol-5-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide **660401-83-2P**, 4-[5-(Pyridin-4-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide **660402-22-2P**, 5-(Methanesulfonyl)-2-[(3-pyridinyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine **660402-23-3P**, 5-(Methanesulfonyl)-2-[(4-pyridinyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine **660402-24-4P**, 2-(5-Cyclohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)-5-(methanesulfonyl)pyridine **660402-59-5P**, 5-(5-Cyclohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)-2-(methanesulfonyl)pyridine **660402-76-6P**, 5-[5-(Pyridin-3-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-2-sulfonic acid amide **660402-77-7P**, 5-[5-(Pyridin-4-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-2-sulfonic acid amide **660402-78-8P**, 5-(5-Cyclohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine-2-sulfonic acid amide **660402-96-0P**, 3-(Methanesulfonyl)-6-[5-(pyridin-3-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine **660402-97-1P**, 3-(Methanesulfonyl)-6-[5-(pyridin-4-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine **660402-98-2P**, 3-(5-Cyclohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)-6-(methanesulfonyl)pyridazine **660403-18-9P**, 6-[5-(Pyridin-3-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine-3-sulfonic acid amide **660403-19-0P**, 6-[5-(Pyridin-4-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine-3-sulfonic acid amide **660403-20-3P**, 6-(5-Cyclohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridazine-3-sulfonic acid amide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**;
USES (Uses)

(COX inhibitor; preparation of triazoles as COX-2 inhibitors for treatment of fever, pain, inflammation, cancer, and dementia)


RN 481052-76-0 HCAPLUS

CN Benzenesulfonamide, 4-[5-(3-pyridinyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 481052-87-3 HCAPLUS

CN Benzenesulfonamide, 4-[5-cyclohexyl-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 481649-86-9 HCAPLUS

CN 3-Pyridinesulfonamide, 6-[5-(3-pyridinyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 481649-87-0 HCAPLUS

CN 3-Pyridinesulfonamide, 6-[5-(4-pyridinyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 481649-91-6 HCAPLUS

CN 3-Pyridinesulfonamide, 6-[5-cyclohexyl-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 660400-74-8 HCAPLUS

CN 1H-1,2,4-Triazole, 5-(1,3-benzodioxol-5-yl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 660400-75-9 HCAPLUS

CN Pyridine, 4-[1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl]- (9CI) (CA INDEX NAME)




RN 660401-41-2 HCAPLUS

CN Pyridine, 2-[5-(1,3-benzodioxol-5-yl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 660401-42-3 HCAPLUS

CN Pyridine, 3-[1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl]- (9CI) (CA INDEX NAME)




RN 660401-43-4 HCAPLUS

CN 1H-1,2,4-Triazole, 5-cyclohexyl-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660401-82-1 HCAPLUS


CN Benzenesulfonamide, 4-[5-(1,3-benzodioxol-5-yl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660401-83-2 HCAPLUS


CN Benzenesulfonamide, 4-[5-(4-pyridinyl)-3-(trifluoromethyl)-1H-1,2,4-

triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 660402-22-2 HCAPLUS

CN Pyridine, 5-(methylsulfonyl)-2-[5-(3-pyridinyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 660402-23-3 HCAPLUS

CN Pyridine, 5-(methylsulfonyl)-2-[5-(4-pyridinyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 660402-24-4 HCAPLUS


CN Pyridine, 2-[5-cyclohexyl-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 660402-59-5 HCAPLUS
 CN Pyridine, 5-[5-cyclohexyl-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 660402-76-6 HCAPLUS
 CN 2-Pyridinesulfonamide, 5-[5-(3-pyridinyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660402-77-7 HCAPLUS
 CN 2-Pyridinesulfonamide, 5-[5-(4-pyridinyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 660402-78-8 HCAPLUS
 CN 2-Pyridinesulfonamide, 5-[5-cyclohexyl-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 660402-96-0 HCAPLUS

CN Pyridazine, 3-(methylsulfonyl)-6-[5-(3-pyridinyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 660402-97-1 HCAPLUS

CN Pyridazine, 3-(methylsulfonyl)-6-[5-(4-pyridinyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660402-98-2 HCAPLUS


CN Pyridazine, 3-[5-cyclohexyl-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]-6-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 660403-18-9 HCAPLUS


CN 3-Pyridazinesulfonamide, 6-[5-(3-pyridinyl)-3-(trifluoromethyl)-1H-1,2,4-

triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 660403-19-0 HCAPLUS

CN 3-Pyridazinesulfonamide, 6-[5-(4-pyridinyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660403-20-3 HCAPLUS

CN 3-Pyridazinesulfonamide, 6-[5-(4-pyridinyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:20012 HCAPLUS

DN 138:73260

TI Preparation of sulfonyl aryl triazoles as anti-inflammatory/analgesic agents

IN Sakya, Subas Man; Shavnya, Andrei; Rast, Bryson

PA Pfizer Products Inc., USA

SO Eur. Pat. Appl., 49 pp.

CODEN: EPXXDW



DT Patent

LA English

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|------|-----------------|------|
|------------|------|------|-----------------|------|

| | | | | | |
|------|---|----|----------|-----------------|----------|
| PI | EP 1273580 | A1 | 20030108 | EP 2002-254275 | 20020701 |
| | EP 1273580 | B1 | 20050615 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| | AT 297913 | E | 20050715 | AT 2002-254275 | 20020701 |
| | CA 2392271 | AA | 20030105 | CA 2002-2392271 | 20020703 |
| | US 2003119835 | A1 | 20030626 | US 2002-188511 | 20020703 |
| | US 6753332 | B2 | 20040622 | | |
| | JP 2003040887 | A2 | 20030213 | JP 2002-196419 | 20020704 |
| | BR 2002002546 | A | 20030513 | BR 2002-2546 | 20020704 |
| | US 2004198735 | A1 | 20041007 | US 2004-829882 | 20040422 |
| | US 6875779 | B2 | 20050405 | | |
| PRAI | US 2001-303232P | P | 20010705 | | |
| | US 2002-188511 | A3 | 20020703 | | |
| OS | MARPAT 138:73260 | | | | |
| GI | | | | | |



AB Title compds. I [A = pyrimidinylsulfonyl, pyridazinylsulfonyl, etc.; R1 = alk(en/yn)yl, alkoxy, alkylcarbonyl, etc.; R3 = H, halo, alk(en/yn)yl, alkoxy, formyl, etc.; R5 = H, halo, OH, SH, etc.] are prepared For instance, N-(5-(methanesulfonyl)pyridin-2-yl)-N'-(1-amino-2,2,2-trifluoroethylidene)hydrazine (preparation given) is condensed with appropriately substituted benzoic acids to produce example compds., e.g., II. Compds. of the invention are evaluated for cyclooxygenase-1 (COX-1) and COX-2 inhibition on canine whole blood; a selected test compound administered at 5 mg/kg (oral gavage) shows significant selectivity for inhibition of COX-2 over COX-1. Example compds. are said to have IC50 values of 0.001 μ M to 3 μ M with respect to COX-2 inhibition. I are useful in the treatment or alleviation of inflammation and other inflammation associated disorders, such as osteoarthritis, rheumatoid arthritis, colon cancer and Alzheimer's disease, in mammals (preferably humans, dogs, cats and livestock).

IC ICM C07D401-04
ICS C07D405-14; A61K031-4196

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

ST sulfonyl aryl triazole antiinflammatory analgesic cyclooxygenase inhibitor prep

IT Intestine, neoplasm
(colon; preparation of sulfonyl aryl triazoles as anti-

inflammatory/analgesic agents)

IT Alzheimer's disease
Anti-Alzheimer's agents
Anti-inflammatory agents
Antiarthritics
Antirheumatic agents
Human
Inflammation
Livestock
Osteoarthritis
Rheumatoid arthritis
(preparation of sulfonyl aryl triazoles as anti-inflammatory/analgesic agents)


IT 481649-84-7P, 6-(5-Phenyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine-3-sulfonic acid amide 481649-85-8P, 6-(5-(Pyridin-2-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine-3-sulfonamide 481649-86-9P, 6-(5-(Pyridin-3-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine-3-sulfonamide 481649-87-0P, 6-(5-(Pyridin-4-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine-3-sulfonamide 481649-88-1P, 6-[5-(2-Fluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 481649-89-2P, 6-[5-(4-Fluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 481649-90-5P, 6-[5-(3-Methylbutyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide 481649-91-6P, 6-(5-Cyclohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine-3-sulfonic acid amide 481649-92-7P, 6-[5-(3-Fluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation);
USES (Uses)
(preparation of sulfonyl aryl triazoles as anti-inflammatory/analgesic agents)

IT 354-37-0, Trifluoroacetamidine 343262-52-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of sulfonyl aryl triazoles as anti-inflammatory/analgesic agents)

IT 481649-93-8P, N-(5-(Methanesulfonyl)-pyridin-2-yl)-N'-(1-amino-2,2,2-trifluoroethylidene)hydrazine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of sulfonyl aryl triazoles as anti-inflammatory/analgesic agents)


IT 481649-85-8P, 6-(5-(Pyridin-2-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine-3-sulfonamide 481649-86-9P, 6-(5-(Pyridin-3-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine-3-sulfonamide 481649-87-0P, 6-(5-(Pyridin-4-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine-3-sulfonamide 481649-91-6P, 6-(5-Cyclohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine-3-sulfonic acid amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation);
USES (Uses)
(preparation of sulfonyl aryl triazoles as anti-inflammatory/analgesic agents)

RN 481649-85-8 HCAPLUS
CN 3-Pyridinesulfonamide, 6-[5-(2-pyridinyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 481649-86-9 HCAPLUS

CN 3-Pyridinesulfonamide, 6-[5-(3-pyridinyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 481649-87-0 HCAPLUS

CN 3-Pyridinesulfonamide, 6-[5-(4-pyridinyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 481649-91-6 HCAPLUS

CN 3-Pyridinesulfonamide, 6-[5-cyclohexyl-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RE.CNT 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:20009 HCAPLUS

DN 138:73259

TI Preparation of sulfonyl aryl triazoles as anti-inflammatory/analgesic agents

IN Rast, Bryson; Sakya, Subas Man; Shavnya, Andrei

PA Pfizer Products Inc., USA

SO Eur. Pat. Appl., 36 pp.


CODEN: EPXXDW

DT Patent


LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | EP 1273576 | A1 | 20030108 | EP 2002-254339 | 20020701 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| | CA 2390181 | AA | 20030105 | CA 2002-2390181 | 20020628 |
| | US 2003125368 | A1 | 20030703 | US 2002-188713 | 20020702 |
| | JP 2003064061 | A2 | 20030305 | JP 2002-196417 | 20020704 |
| | BR 2002002544 | A | 20030513 | BR 2002-2544 | 20020704 |
| PRAI | US 2001-303186P | P | 20010705 | | |
| OS | MARPAT 138:73259 | | | | |
| GI | | | | | |



I



II

AB Title compds. I [$m = 0-2$; R₁ = alk(en/yn)yl, alkoxy, alkylcarbonyl, formyl, formamidyl, etc.; R₃ = H, halo, alk(en/yn)yl, alkoxy, etc.; R₅ = alkyl] are prepared. For instance, 4-hydrazinobenzenesulfonamide•HCl was condensed with trifluoroacetamide to give 4-[N'-(1-amino-2,2,2-trifluoroethylidene)hydrazino]benzenesulfonamide. This intermediate was condensed with benzoyl chloride (CH₂Cl₂, pyridine, 0°) to give II. Compds. of the invention are evaluated for cyclooxygenase-1 (COX-1) and COX-2 inhibition on canine whole blood; a selected test compound administered at 5 mg/kg (oral gavage) shows significant selectivity for inhibition of COX-2 over COX-1. Example compds. are said to have IC₅₀ values of 0.001 μM to 3 μM with respect to COX-2 inhibition. I are useful in the treatment or alleviation of inflammation and other inflammation associated disorders, such as osteoarthritis, rheumatoid arthritis, colon cancer and Alzheimer's disease, in mammals (preferably humans, dogs, cats and livestock).

IC ICM C07D249-08

ICS C07D401-04; C07D405-04; A61K031-4196; A61P029-00

- CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
- ST sulfonyl aryl triazole antiinflammatory analgesic cyclooxygenase inhibitor
prepn
- IT Intestine, neoplasm
(colon; preparation of sulfonyl aryl triazoles as anti-
inflammatory/analgesic agents)
- IT Alzheimer's disease
Anti-Alzheimer's agents
Anti-inflammatory agents
Antiarthritics
Antirheumatic agents
Human
Inflammation
Livestock
Osteoarthritis
Rheumatoid arthritis
(preparation of sulfonyl aryl triazoles as anti-inflammatory/analgesic
agents)
- IT 363-24-6, PGE2 54397-85-2, TXB2 329900-75-6, COX 2 329967-85-3,
COX-1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of sulfonyl aryl triazoles as anti-inflammatory/analgesic
agents)
- IT 481052-74-8P, 4-(5-Phenyl-3-trifluoromethyl-[1,2,4]triazol-1-
yl)benzenesulfonamide 481052-75-9P, 4-(5-(Pyridin-2-yl)-3-
trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfonamide
481052-76-0P, 4-(5-(Pyridin-3-yl)-3-trifluoromethyl-[1,2,4]triazol-
1-yl)benzenesulfonamide 481052-77-1P, 4-(5-(Furan-2-yl)-3-
trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfonamide
481052-78-2P, 4-[5-(Tetrahydrofuran-2-yl)-3-trifluoromethyl-
[1,2,4]triazol-1-yl]benzenesulfonamide 481052-79-3P,
4-[5-(Tetrahydropyran-4-yl)-3-trifluoromethyl-[1,2,4]triazol-1-
yl]benzenesulfonamide 481052-80-6P, 4-[5-(2,2-
Dimethyltetrahydropyran-4-yl)-3-trifluoromethyl-[1,2,4]triazol-1-
yl]benzenesulfonamide 481052-81-7P, 4-[5-(4-Fluorophenyl)-3-
trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 481052-82-8P,
4-[5-(3-Fluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-
yl]benzenesulfonamide 481052-83-9P, 4-[5-(2,2-Dimethylpropyl)-3-
trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 481052-84-0P,
4-[5-(2-Methylbutyl)-3-trifluoromethyl-[1,2,4]triazol-1-
yl]benzenesulfonamide 481052-85-1P, 4-[5-(3-Methylbutyl)-3-
trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide
481052-86-2P, 4-(5-Cyclobutyl-3-trifluoromethyl-[1,2,4]triazol-1-
yl)benzenesulfonamide 481052-87-3P, 4-(5-Cyclohexyl-3-
trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfonamide
481052-88-4P, 4-[5-(4-tert-Butylcyclohexyl)-3-trifluoromethyl-
[1,2,4]triazol-1-yl]benzenesulfonamide 481052-89-5P,
4-[5-(3-Methylcyclohexyl)-3-trifluoromethyl-[1,2,4]triazol-1-
yl]benzenesulfonamide 481052-90-8P, 4-[5-(3-Methoxycyclohexyl)-3-
trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide
481052-91-9P, 4-(5-Cyclopentyl-3-trifluoromethyl-[1,2,4]triazol-1-
yl)benzenesulfonamide 481052-92-0P, 4-(5-(Isobutyl)-3-(trifluoromethyl)-
[1,2,4]triazol-1-yl)benzenesulfonamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation);
USES (Uses)
(preparation of sulfonyl aryl triazoles as anti-inflammatory/analgesic
agents)
- IT 354-37-0, Trifluoroacetamide 27918-19-0, 4-Hydrazinobenzenesulfonamide

hydrochloride

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of sulfonyl aryl triazoles as anti-inflammatory/analgesic agents)

IT 481052-73-7P, 4-[N'-(1-Amino-2,2,2-trifluoroethylidene)hydrazino]benzenesulfonamide

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of sulfonyl aryl triazoles as anti-inflammatory/analgesic agents)

IT 481052-75-9P, 4-(5-(Pyridin-2-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfonamide 481052-76-0P, 4-(5-(Pyridin-3-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfonamide 481052-77-1P, 4-(5-(Furan-2-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfonamide 481052-78-2P, 4-[5-(Tetrahydrofuran-2-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 481052-79-3P, 4-[5-(Tetrahydropyran-4-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 481052-80-6P, 4-[5-(2,2-Dimethyltetrahydropyran-4-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 481052-86-2P, 4-(5-Cyclobutyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfonamide 481052-87-3P, 4-(5-Cyclohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfonamide 481052-88-4P, 4-[5-(4-tert-Butylcyclohexyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 481052-89-5P, 4-[5-(3-Methylcyclohexyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 481052-90-8P, 4-[5-(3-Methoxycyclohexyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 481052-91-9P, 4-(5-Cyclopentyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfonamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation);
USES (Uses)

(preparation of sulfonyl aryl triazoles as anti-inflammatory/analgesic agents)


RN 481052-75-9 HCAPLUS

CN Benzenesulfonamide, 4-[5-(2-pyridinyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 481052-76-0 HCAPLUS

CN Benzenesulfonamide, 4-[5-(3-pyridinyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 481052-77-1 HCAPLUS

CN Benzenesulfonamide, 4-[5-(2-furanyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 481052-78-2 HCAPLUS

CN Benzenesulfonamide, 4-[5-(tetrahydro-2-furanyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 481052-79-3 HCAPLUS

CN Benzenesulfonamide, 4-[5-(tetrahydro-2H-pyran-4-yl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 481052-80-6 HCAPLUS

CN Benzenesulfonamide, 4-[5-(tetrahydro-2,2-dimethyl-2H-pyran-4-yl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 481052-86-2 HCAPLUS

CN Benzenesulfonamide, 4-[5-cyclobutyl-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 481052-87-3 HCAPLUS

CN Benzenesulfonamide, 4-[5-cyclohexyl-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 481052-88-4 HCAPLUS

CN Benzenesulfonamide, 4-[5-[4-(1,1-dimethylethyl)cyclohexyl]-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 481052-89-5 HCAPLUS

CN Benzenesulfonamide, 4-[5-(3-methylcyclohexyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 481052-90-8 HCAPLUS

CN Benzenesulfonamide, 4-[5-(3-methoxycyclohexyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 481052-91-9 HCAPLUS
CN Benzenesulfonamide, 4-[5-cyclopentyl-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>